Cidara Therapeutics: All Stars Aligning In Favor Of CD388

Summary

• Cidara Therapeutics' CD388 is a long-acting influenza antiviral aimed at providing universal protection with a single yearly dose for each flu season.
• In contrast to vaccines, CD388's efficacy is not dependent on circulating strains or on an intact patient immune system. CD388 is ideal for pandemic preparedness and for high-risk patients.
• Readout of a randomized ph2b trial of CD388 is expected by the end of June, with the potential to serve as one of the two needed trials for approval.
• The more severe than usual 2024-2025 flu season significantly increases the probability of a positive readout, which in turn would considerably de-risk CDTX and justify considerable upside potential.

Jonathan Kitchen

Thesis overview

This is my 4th coverage of Cidara Therapeutics (NASDAQ:CDTX). At the time of writing, CDTX is trading at around +90% since my last coverage. CDTX has always been a long-term investment for me as explained in prior articles, but the

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CDTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.